200548 results about "Polymer chemistry" patented technology

A process for reducing solvent contents in drug-containing polymeric compositions may be utilized to reduce the solvent content in implantable medical device wherein the compositions are in reservoirs. Specifically, the solvent contents in the drug-containing polymeric compositions are first reduced by one or more conventional drying methods, to a range from about 0.5 weight percent to about 10 weight percent of the total weight of the polymeric composition. Subsequently, the drug-containing polymeric compositions are further treated by a low temperature drying method for further reduction of the solvent content.

An organic electroluminescence device includes: a cathode; an anode; and a single-layered or multilayered organic thin-film layer provided between the cathode and the anode. In the organic electroluminescence device, the organic thin-film layer includes at least one emitting layer, and the at least one emitting layer includes at least one phosphorescent material and a host material represented by the following Formula (1).Ra—Ar1—Ar2—Rb   (1)In Formula (1):Ra and Rb each represent a substituted or non-substituted benzene ring or a substituted or non-substituted condensed aromatic hydrocarbon ring selected from a group consisting of a naphthalene ring, a chrysene ring, a fluoranthene ring, a triphenylene ring, a phenanthrene ring, a benzophenanthrene ring, a dibenzophenanthrene ring, a benzotriphenylene ring, a benzochrysene ring and a picene ring; andAr1 and Ar2 each represent a substituted or non-substituted benzene ring or a substituted or non-substituted condensed aromatic hydrocarbon ring selected from a group consisting of a naphthalene ring, a chrysene ring, a fluoranthene ring, a triphenylene ring, a benzophenanthrene ring, a dibenzophenanthrene ring, a benzotriphenylene ring, a benzochrysene ring and a picene ring.

An emulsion is useful in allowing a wide variety of gene products to be expressed via eukaryotic in vitro expression. The emulsion comprises a silicone based surfactant, a hydrophobic phase and a hydrophilic phase; wherein the hydrophilic phase comprises a plurality of compartments containing a functional in vitro eukaryotic expression system.

Electrolytic capacitors having low equivalent series resistance and low leakage current are described. The electrolytic capacitors include a solid electrolyte layer of a conductive material in particular a conductive polymer, and an outer layer that includes binders, polymeric anions and conductive polymers (e.g., polythiophenes). Also described is a method of preparing electrolytic capacitors that involves forming the conductive polymer of the solid electrolyte layer in situ by means of chemical oxidative polymerization or electrochemical polymerization. Electronic circuits that include the electrolytic capacitors are also described.

Graphitic nanotubes, which includes tubular fullerenes (commonly called "buckytubes") and fibrils, which are functionalized by chemical substitution or by adsorption of functional moieties. More specifically the invention relates to graphitic nanotubes which are uniformly or non-uniformly substituted with chemical moieties or upon which certain cyclic compounds are adsorbed and to complex structures comprised of such functionalized fibrils linked to one another. The invention also relates to methods of introducing functional groups onto the surface of such fibrils.

A coating composition is disclosed which comprises an aqueous polymeric matrix, a hydrophilic polymer, a colloidal metal oxide and a crosslinker. The coating composition when applied on medical devices is hydrophilic, shows improved lubricity, abrasion resistance and substrate adhesion on metallic or plastic substrates. The coating also shows improved water sheeting thus providing the coated substrates with anti-fog properties. The coating absorbs aqueous dye or stain solutions making the substrate suitable for printing.